Amgen Inc (AMGN) Stock Price, Quote & News

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 805 447 1000

Fax: 805 447 1010

Website: www.amgen.com

Address:

One Amgen Center Drive, Thousand Oaks, United States

profit_guru Sep. 10 at 4:57 PM

$AMGN - it usually rallies on Friday during option expiration….might see 285 by Friday…imo

0 · Reply

theflynews Sep. 10 at 4:08 PM

Biotech Alert: Searches spiking for these stocks today - $AMGN - https://thefly.com/permalinks/entry.php/AMGNid4196224?1757520276C38

0 · Reply

highnihilism Sep. 10 at 3:36 PM

$AMGN Amgen announced a $600M Science & Innovation Center in Thousand Oaks. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, nostalgia, handmade crafts, domestic charm, heritage demand). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”

0 · Reply

profit_guru Sep. 10 at 3:36 PM

$AMGN - way oversold…might close green…near term 290…imo

0 · Reply

Quantumup Sep. 10 at 1:24 PM

Truist🏁 $JANX Buy/$100: Truist said: We initiate coverage of Janux Therapeutics ( $JANX ) with a Buy rating and $100 PT. [ $NVS $AMGN $JNJ $AZN ] Truist added: We believe the company's proprietary platforms (TRACTr and TRACIr) have the potential to overcome historical limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. Lead asset JANX007 has best-in-class potential in prostate cancer, and with multiple readouts across 2025, we see a catalyst rich year ahead. Where many peers have stumbled, Janux's masking technology offers a differentiated path to both efficacy and safety. With key data updates expected in the back half of 2025, we anticipate meaningful upside for investors.

0 · Reply

SuperGreenToday Sep. 10 at 3:25 AM

$AMGN The entire thesis rests on the margin expansion from its new product portfolio and the successful integration of Horizon Therapeutics outweighing the massive cliff from its aging biologic blockbusters.

0 · Reply

ares_91361 Sep. 9 at 9:14 PM

$AMGN after hours is up is something happening?

2 · Reply

profit_guru Sep. 9 at 8:02 PM

$AMGN - way oversold…imo

0 · Reply

StockAutoPro Sep. 9 at 7:30 PM

$AMGN: Buy target $278.62 Sell target $294.65 Potential growth observed in biotechnology firm focused on innovative human therapeutics. Consider for portfolio diversification.

0 · Reply

Thestocktraderhubzee Sep. 9 at 11:02 AM

WATCHLIST SEP 09 2025. $SERV Following Acquisition of Phantom Auto, Serve Robotics Adds Voysys Ultra-Low Latency Teleoperation Technology to Level 4 Autonomy Platform Offering $ACRS Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress $AMGN Amgen And Kyowa Kirin Highlight Rocatinlimab Long-Term Durability Of Response In Adults From Global Phase 3 ASCEND Atopic Dermatitis Program $CRNC Cerence AI Demonstrates Multi-Modal xUI Capabilities Integrating Voice Touch And Vision Detection At IAA Mobility 2025 $AMBO Ambow Education Launches HybriU® 3D Mobile Station, Redefining 3D Production and Broadcasting with Seamless Portability

0 · Reply

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

ABBV AZN GSK NVO NVS SNY LLY

Sep 9, 2025, 7:12 PM EDT - 1 day ago

US FDA to step up enforcement of pharma ads, sends enforcement letters

LLY MRK

Sep 9, 2025, 11:41 AM EDT - 1 day ago

Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 12:12 AM EDT - 2 days ago

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

Sep 8, 2025, 8:04 PM EDT - 2 days ago

AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Sep 6, 2025, 2:07 AM EDT - 4 days ago

September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog

AMZN BA CRM CSCO CVX DIS HON

Sep 4, 2025, 4:01 PM EDT - 6 days ago

AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

Sep 3, 2025, 2:09 PM EDT - 7 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AZN BIIB GILD JNJ LLY MRK

Sep 3, 2025, 1:49 PM EDT - 7 days ago

Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 9:01 AM EDT - 8 days ago

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

Sep 2, 2025, 9:00 AM EDT - 8 days ago

Amgen to invest $600 million in new research and development facility in California

Aug 29, 2025, 4:01 PM EDT - 12 days ago

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

Aug 27, 2025, 1:23 PM EDT - 14 days ago

Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco

AS COST DASH MRK MU

Aug 25, 2025, 9:00 AM EDT - 16 days ago

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

Aug 25, 2025, 6:33 AM EDT - 16 days ago

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

RPRX

Aug 14, 2025, 3:06 PM EDT - 27 days ago

Back To Basics: Why I Favor Amgen Over Johnson & Johnson

JNJ

Aug 7, 2025, 12:23 PM EDT - 4 weeks ago

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

AMZN BA CRM CVX DIS HD HON

Aug 6, 2025, 2:19 PM EDT - 5 weeks ago

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Aug 6, 2025, 10:56 AM EDT - 5 weeks ago

Why I Still Don't Think Amgen Is A Buy

Aug 5, 2025, 9:48 PM EDT - 5 weeks ago

Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:39 PM EDT - 5 weeks ago

Amgen beats on Q2 revenue, slightly raises guidance

Aug 5, 2025, 4:03 PM EDT - 5 weeks ago

Amgen quarterly results beat Wall Street estimates

Aug 5, 2025, 4:01 PM EDT - 5 weeks ago

AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Aug 5, 2025, 11:01 AM EDT - 5 weeks ago

3 Dividend Stocks for August 2025

BMY POR

Aug 5, 2025, 8:00 AM EDT - 5 weeks ago

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board

Aug 4, 2025, 11:02 AM EDT - 5 weeks ago

Buy or Sell Amgen Stock Ahead of Its Earnings?

Aug 1, 2025, 4:01 PM EDT - 5 weeks ago

AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND

Aug 1, 2025, 12:01 PM EDT - 5 weeks ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AZN BMY GILD GSK JNJ LLY

Aug 1, 2025, 8:31 AM EDT - 5 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY ARGX AZN BAX BIIB

Aug 1, 2025, 6:54 AM EDT - 5 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY ARGX AZN BAX BIIB

Jul 31, 2025, 4:01 PM EDT - 5 weeks ago

AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS

Jul 31, 2025, 3:35 PM EDT - 5 weeks ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AZN BMY GILD GSK JNJ LLY

Jul 31, 2025, 3:00 PM EDT - 5 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AZN BMY GILD GSK JNJ LLY

Jul 31, 2025, 2:28 PM EDT - 5 weeks ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AZN BMY GILD GSK JNJ LLY

Jul 31, 2025, 2:19 PM EDT - 5 weeks ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AZN BMY GSK

Jul 31, 2025, 1:48 PM EDT - 5 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AZN BMY GILD GSK JNJ LLY

Jul 30, 2025, 12:37 PM EDT - 6 weeks ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

BBIO INSM

Jul 22, 2025, 4:07 PM EDT - 7 weeks ago

Dow Leads as Health Care Stocks Merck and Amgen Gain: Stock Market Today

MRK

Jul 21, 2025, 7:00 AM EDT - 7 weeks ago

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

Jul 18, 2025, 1:51 PM EDT - 7 weeks ago

Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More

KO TRIN

Jul 15, 2025, 11:40 PM EDT - 2 months ago

Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns

Jul 15, 2025, 8:00 AM EDT - 2 months ago

Amgen: Great Starting Yield For This Wealth Compounder

Jul 9, 2025, 5:29 PM EDT - 2 months ago

Amgen: A Defensive Biotech With Yield And Optionality

Jul 2, 2025, 1:22 PM EDT - 2 months ago

Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran

CAT FCX HON

Jun 30, 2025, 9:10 AM EDT - 2 months ago

Amgen's gastric cancer drug meets late-stage trial goal

Jun 30, 2025, 9:00 AM EDT - 2 months ago

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

Jun 24, 2025, 2:54 PM EDT - 2 months ago

Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues

Jun 24, 2025, 9:25 AM EDT - 2 months ago

What's Happening With Amgen Stock?

Jun 24, 2025, 1:44 AM EDT - 2 months ago

Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript

Jun 23, 2025, 6:10 PM EDT - 2 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

GPCR LLY NVO PFE REGN VKTX XBI

profit_guru Sep. 10 at 4:57 PM

$AMGN - it usually rallies on Friday during option expiration….might see 285 by Friday…imo

0 · Reply

theflynews Sep. 10 at 4:08 PM

Biotech Alert: Searches spiking for these stocks today - $AMGN - https://thefly.com/permalinks/entry.php/AMGNid4196224?1757520276C38

0 · Reply

highnihilism Sep. 10 at 3:36 PM

0 · Reply

profit_guru Sep. 10 at 3:36 PM

$AMGN - way oversold…might close green…near term 290…imo

0 · Reply

Quantumup Sep. 10 at 1:24 PM

0 · Reply

SuperGreenToday Sep. 10 at 3:25 AM

0 · Reply

ares_91361 Sep. 9 at 9:14 PM

$AMGN after hours is up is something happening?

2 · Reply

profit_guru Sep. 9 at 8:02 PM

$AMGN - way oversold…imo

0 · Reply

StockAutoPro Sep. 9 at 7:30 PM

$AMGN: Buy target $278.62 Sell target $294.65 Potential growth observed in biotechnology firm focused on innovative human therapeutics. Consider for portfolio diversification.

0 · Reply

Thestocktraderhubzee Sep. 9 at 11:02 AM

0 · Reply

KenFaulkenberry Sep. 9 at 1:12 AM

$AMGN Amgen (AMGN) Stock Analysis Amgen combines steady cash flow from blockbuster drugs with long-term upside potential from its research pipeline and strategic acquisitions. Its history of increasing dividends and share repurchases appeals to income and total return investors alike. For those seeking exposure to the biotech sector with lower volatility and a shareholder-friendly focus, Amgen represents a good large-cap opportunity. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of AMGN? https://dividendvaluebuilder.com/amgen-amgn-dividend-stock-analysis/

0 · Reply

masonat Sep. 9 at 12:53 AM

$NKTR strange PR from $AMGN about Roca, a potential Rezpeg competitor. NKTR could be up again tomorrow. https://www.prnewswire.com/news-releases/amgen-and-kyowa-kirin-announce-top-line-results-from-rocatinlimab-phase-3-ascend-long-term-extension-study-in-adults-with-moderate-to-severe-atopic-dermatitis-302549965.html

2 · Reply

johnwatson2 Sep. 8 at 4:40 PM

$AMGN finally man… been waiting for this dogpile to finally let go at go down to 272

0 · Reply

dogDazeSummer Sep. 8 at 3:38 PM

$IFRX HCW, Cont: “INF904’s biochemical properties were compared to a market comparator, avacopan, brand name TAVNEOS, $AMGN (1) demonstrated approximately a 3x higher Cmax and approximately a 10x higher systemic exposure (AUClast) vs. a comparable dose of avacopan, (2) showed significantly increased blocking of C5a activity (i.e., >90% blocking), and (3) exhibited faster achievement of therapeutic exposures with broader therapeutic index. Because of compelling inflammatory cascade inhibition at lower doses, the drug’s properties allow for the exploration of various dosing in numerous indications that could open significant market opportunities for the company (e.g., immuno-dermatology and immuno-inflammatory indications, including nephrology, neurology, and hematology). In this way, INF904 has the potential to become a pipeline in a pill.

0 · Reply

Polip Sep. 7 at 3:41 PM

$IDYA HUGE! Better than $AMGN ! GAP up tomorrow!

1 · Reply

GemsBot Sep. 6 at 7:30 AM

1 of 11 $AAPL $AMGN $AMZN Daily and 30 min charts of the DJIA Components with the SSI indicator, a proprietary indicator based exclusively on the eSignal platform, are posted here weekends … see 2/11

0 · Reply

dogDazeSummer Sep. 5 at 1:24 PM

$IFRX Interesting when Seedhouse suggested 904 for PG and Niels shut that down for how long it would take/ new study ——and not be as profitable as IV / vilo. Why would he do this if there isn’t some plan to ask FDA to retroactively move the goal posts to 50% wound improvement? There is 100% fact c5a is implicated and the mechanism works (avacopan via $AMGN). They may need a partner to lobby FDA, but he also said the FDA has *been reaching out to them*. This FDA is different than anything we’ve seen. Slashing $MRNA $PFE who don’t have placebo controlled double blind studies; Then Fast tracking approval for drugs *that have clean safety profiles* and have been proven effective in study after study. Now is perfect time to sign partner and submit FDA approval w vilo PG. This is why the PG P2 (and P3) studies are being discussed and highlighted in upcoming conferences. Cantors Aug 7 update: “the FDA was interested in the pain endpoint and pain data could be informative…”

1 · Reply

Quantumup Sep. 4 at 1:14 PM

Guggenheim🏁 $JANX Buy/$72. $NVS $AMGN $JNJ $AZN BNTX MRK BMY Guggenheim said in its initiation report:

0 · Reply

Quantumup Sep. 4 at 12:56 PM

Barclays🏁 $IDYA Overweight/$40. Citizens🏁 $IDYA Market Outperform/$41. $ZLAB $AMGN $DSNKY $PFE GILD AZN RHHBY Barclays and Citizens JMP said in their initiation reports:

0 · Reply

topstockalerts Sep. 4 at 12:47 PM

Nvidia venture arm is making its first investment in quantum computing company Quantinuum, valuing the firm at $ 10B, according to Bloomberg sources. The $ 600M funding round, which could be announced as soon as Thursday, also includes HON (which owns about 54% of Quantinuum), QED Investors, JPM, Mitsui, and AMGN. This move signals NVDA’s growing interest in quantum computing, joining other major investors in backing the next-generation technology. $NVDA $HON $AMGN

2 · Reply

StockAutoPro Sep. 4 at 3:32 AM

$AMGN: Buy target $281.85 Sell target $298.04 Strong pipeline progress indicates potential for growth in biotech sector stock.

0 · Reply

JarvisFlow Sep. 3 at 4:42 PM

Raymond James has updated their rating for Amgen ( $AMGN ) to Market Perform.

0 · Reply

Market Cap	150.73B
Revenue (ttm)	33.42B
Net Income (ttm)	4.09B
EPS (ttm)	N/A
PE Ratio	12.85
Forward PE	13.28
Profit Margin	12.24%
Debt to Equity Ratio	7.57

Volume	2,150,600
Avg Vol	2,009,434
Day's Range	N/A - N/A
Shares Out	538.36M
Stochastic %K	25%
Beta	0.49
Analysts	Sell
Price Target	$315.07